查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790417

紅色生物技術市場規模、佔有率和趨勢分析報告：按產品、最終用途、地區和細分市場預測，2025 年至 2030 年

Red Biotechnology Market Size, Share & Trends Analysis Report By Product, By End Use (Academic Research Institutes, CMOs & CROs, Pharmaceutical & Biotechnology Companies, Others), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10個工作天內

價格

紅色生物技術市場摘要

2024 年全球紅色生物技術市場價值估計為 5,465.9 億美元，預計到 2030 年將達到 9,977.4 億美元，2025 年至 2030 年期間的複合年成長率為 10.5%。個人化醫療需求的不斷成長、對生物技術產品研究的高投入以及基因研究的進步正在塑造該行業。

紅色生物技術涉及生物技術應用，例如幹細胞、基因治療、基因工程以及新藥和疫苗的開發。紅色生物技術是利用生物體改善醫療保健並幫助人體抵抗疾病的過程。它是現代醫學技術的一部分。它在製藥業和醫療領域的應用源於其減輕人類痛苦和改善生活品質的潛力。擴大使用基因工程來生產生物藥物是一個主要趨勢。這涉及使用重組DNA技術來創建能夠批量生產特定蛋白質（例如治療性抗體）的基因改造生物。

預計市場在預測期內將經歷良好成長。疾病管理方面已經取得了重大進展，從治療急性微生物感染疾病的抗生素到抗愛滋病毒/愛滋病藥物等慢性疾病，包括有助於控制愛滋病的疊氮胸苷。許多製藥公司正在開發和生產用於治療糖尿病和阿茲海默症和帕金森氏症等神經系統疾病的在研發線產品。根據clinicaltrials.gov的數據，截至 2021 年 1 月，有 126 種藥物正在進行治療阿茲海默症的臨床試驗，其中 28 種正處於 III 期試驗階段。發酵技術廣泛應用於生命科學和醫療保健領域，對市場成長產生了積極影響。

這個市場持續成長，並具有加速醫學進步和改變遺傳性疾病識別方式的巨大潛力。新的檢測方法可以檢測出疾病相關基因DNA序列的變化，而早期檢測對於透過早期治療預防或減緩疾病進展至關重要。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章紅色生物技術市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 紅色生物技術市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 紅色生物技術市場：通路分析

第4章紅色生物技術市場：產品估計與趨勢分析

  • 產品細分儀表板
  • 紅色生物技術市場：產品差異分析
  • 全球紅色生物技術市場規模與趨勢分析（按產品，2018-2030 年）
  • 單株抗體
  • 多株抗體
  • 重組蛋白
  • 疫苗
  • 細胞免疫療法產品
  • 基因治療產品
  • 細胞治療產品
  • 組織工程產品
  • 幹細胞
  • 細胞培養
  • 病毒載體
  • 酵素
  • 套件和試劑
  • 動物模型
  • 分子診斷
  • 其他

第5章紅色生物技術市場：最終用途估計與趨勢分析

  • 最終用途細分儀表板
  • 紅色生物技術市場：最終用途差異分析
  • 全球紅色生物技術市場規模和趨勢分析（按最終用途，2018-2030 年）
  • 學術研究機構
  • CMO和CRO
  • 製藥和生物技術公司
  • 其他

第6章紅色生物技術市場：區域估計與趨勢分析

  • 區域市場儀表板
  • 2024 年及 2030 年區域市場佔有率分析
  • 紅色生物技術市場（按地區）: 關鍵要點
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • Key company heat map analysis, 2024
  • 公司簡介
    • Merck KGaA
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Gilead Sciences, Inc.
    • Biogen
    • Amgen Inc.
    • Celgene Corporation（acquired by Bristol-Myers Squibb Company）
Product Code: GVR-4-68040-042-9

Red Biotechnology Market Summary

The global red biotechnology market size was estimated at USD 546.59 billion in 2024, and is projected to reach USD 997.74 billion by 2030, growing at a CAGR of 10.5% from 2025 to 2030. The increasing demand for personalized medicine, high investment in the R&D of biotechnology products, and advances in genetic research are shaping the field.

Red biotechnology deals with biotechnological applications such as stem cells, gene therapy, genetic engineering, and the development of new drugs and vaccines. Red biotechnology is a process that uses organisms to improve health care and aid the body in fighting diseases. It is a subset of modern technology used in the field of medicine. It finds application in the pharmaceutical industry and the medical sector, as it helps alleviate human suffering and improves the quality of life. The increasing usage of genetic engineering to produce biological medicine is one of the major trends. This includes using recombinant DNA technology to create genetically modified organisms capable of producing large amounts of a specific protein, such as a therapeutic antibody.

The market is expected to witness lucrative growth during the forecast period. It has made significant advancements in disease control, from antibiotics for treating acute microbial infections to chronic conditions such as anti-HIV/AIDS, including azidothymidine, which has helped manage AIDS. Many pharmaceutical companies are developing and manufacturing pipeline products for diabetes and neurological disorders such as Alzheimer's and Parkinson's disease. According to clinicaltrials.gov, 126 agents were in clinical trials for the treatment of Alzheimer's disease as of January 2021, with 28 treatments in phase III trials. Fermentation technology is widely used in the life sciences and healthcare sectors, positively impacting market growth.

The market is still growing, with significant potential for driving medical advancements and transforming the identification of diseases caused by genetic factors. Novel tests can detect changes in the DNA sequence of genes linked to diseases, and early detection is a crucial factor in avoiding disease or slowing its progression through early treatment.

Global Red Biotechnology Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global red biotechnology market report based on product, end-use, and region:

  • Product Outlook (Revenue, USD Billion, 2018 - 2030)
  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Cell-Based Immunotherapy Products
  • Gene Therapy Products
  • Cell Therapy Products
  • Tissue-Engineered Products
  • Stem Cells
  • Cell Culture
  • Viral Vector
  • Enzymes
  • Kits and Reagents
  • Animal models
  • Molecular diagnostics
  • Others
  • End-User Outlook (Revenue, USD Billion, 2018 - 2030)
  • Academic Research Institutes
  • CMOs & CROs
  • Pharmaceutical & Biotechnology Companies
  • Others
  • Regional Outlook (Revenue, USD Billion, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Red Biotechnology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Red Biotechnology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Red Biotechnology Market: Pipeline Analysis

Chapter 4. Red Biotechnology Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. Red Biotechnology Market: Product Movement Analysis
  • 4.3. Global Red Biotechnology Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Billion)
  • 4.4. Monoclonal Antibodies
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Polyclonal Antibodies
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.6. Recombinant Proteins
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.7. Vaccines
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.8. Cell-Based Immunotherapy Products
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.9. Gene Therapy Products
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.10. Cell Therapy Products
    • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.11. Tissue - Engineered Products
    • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.12. Stem Cells
    • 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.13. Cell Culture
    • 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.14. Viral Vector
    • 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.15. Enzymes
    • 4.15.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.16. Kits and Reagents
    • 4.16.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.17. Animal Models
    • 4.17.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.18. Molecular Diagnostics
    • 4.18.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.19. Others
    • 4.19.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Red Biotechnology Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Segment Dashboard
  • 5.2. Red Biotechnology Market: End Use Movement Analysis
  • 5.3. Global Red Biotechnology Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
  • 5.4. Academic Research Institutes
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. CMOs & CROs
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Pharmaceutical & Biotechnology Companies
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.7. Others
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Red Biotechnology Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Red Biotechnology Market by Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2. Canada
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.3. Mexico
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. Europe
    • 6.5.1. UK
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.2. Germany
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.3. France
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.4. Italy
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.5. Spain
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.6. Norway
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.7. Sweden
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework/ reimbursement structure
      • 6.5.7.3. Competitive scenario
      • 6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.8. Denmark
      • 6.5.8.1. Key country dynamics
      • 6.5.8.2. Regulatory framework/ reimbursement structure
      • 6.5.8.3. Competitive scenario
      • 6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.2. China
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.3. India
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.4. Australia
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.5. South Korea
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.6. Thailand
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.2. Argentina
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.3. UAE
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key country dynamics
      • 6.8.4.2. Regulatory framework/ reimbursement structure
      • 6.8.4.3. Competitive scenario
      • 6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company heat map analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Merck KGaA
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. F. Hoffmann-La Roche Ltd
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Pfizer Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Regeneron Pharmaceuticals, Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. AstraZeneca
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Takeda Pharmaceutical Company Limited
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Gilead Sciences, Inc.
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Biogen
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Amgen Inc.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Celgene Corporation (acquired by Bristol-Myers Squibb Company)
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiativesa

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global red biotechnology market, by region, 2018 - 2030 (USD Billion)
  • Table 3 Global red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 4 Global red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 5 North America red biotechnology market, by country, 2018 - 2030 (USD Billion)
  • Table 6 North America red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 7 North America red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 8 U.S. red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 9 U.S. red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 10 Canada red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 11 Canada red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 12 Mexico red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 13 Mexico red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 14 Europe red biotechnology market, by country, 2018 - 2030 (USD Billion)
  • Table 15 Europe red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 16 Europe red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 17 Germany red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 18 Germany red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 19 UK red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 20 UK red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 21 France red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 22 France red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 23 Italy red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 24 Italy red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 25 Spain red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 26 Spain red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 27 Denmark red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 28 Denmark red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 29 Sweden red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 30 Sweden red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 31 Norway red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 32 Norway red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 33 Asia Pacific red biotechnology market, by country, 2018 - 2030 (USD Billion)
  • Table 34 Asia Pacific red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 35 Asia Pacific red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 36 China red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 37 China red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 38 Japan red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 39 Japan red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 40 India red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 41 India red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 42 South Korea red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 43 South Korea red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 44 Australia red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 45 Australia red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 46 Thailand red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 47 Thailand red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 48 Latin America red biotechnology market, by country, 2018 - 2030 (USD Billion)
  • Table 49 Latin America red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 50 Latin America Academic research institutes market, by end use, 2018 - 2030 (USD Billion)
  • Table 51 Latin America red biotechnology market, by application, 2018 - 2030 (USD Billion)
  • Table 52 Brazil red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 53 Brazil red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 54 Argentina red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 55 Argentina red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 56 MEA red biotechnology market, by region, 2018 - 2030 (USD Billion)
  • Table 57 MEA red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 58 MEA red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 59 South Africa red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 60 South Africa red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 61 Saudi Arabia red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 62 Saudi Arabia red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 63 UAE red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 64 UAE red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 65 Kuwait red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 66 Kuwait red biotechnology market, by end use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Red biotechnology market: market outlook
  • Fig. 10 Red biotechnology competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Red biotechnology market driver impact
  • Fig. 16 Red biotechnology market restraint impact
  • Fig. 17 Red biotechnology market strategic initiatives analysis
  • Fig. 18 Red biotechnology market: product movement analysis
  • Fig. 19 Red biotechnology market: product outlook and key takeaways
  • Fig. 20 Monoclonal antibodies market estimates and forecast, 2018 - 2030
  • Fig. 21 Polyclonal antibodies market estimates and forecast, 2018 - 2030
  • Fig. 22 Recombinant proteins market estimates and forecast, 2018 - 2030
  • Fig. 23 Vaccines market estimates and forecast, 2018 - 2030
  • Fig. 24 Cell-based immunotherapy products market estimates and forecast, 2018 - 2030
  • Fig. 25 Gene therapy products market estimates and forecast, 2018 - 2030
  • Fig. 26 Cell therapy products market estimates and forecast, 2018 - 2030
  • Fig. 27 Tissue - engineered products market estimates and forecast, 2018 - 2030
  • Fig. 28 Stem cells market estimates and forecast, 2018 - 2030
  • Fig. 29 Cell culture market estimates and forecast, 2018 - 2030
  • Fig. 30 Viral vector market estimates and forecast, 2018 - 2030
  • Fig. 31 Enzymes market estimates and forecast, 2018 - 2030
  • Fig. 32 Kits and reagents therapy market estimates and forecast, 2018 - 2030
  • Fig. 33 Animal models market estimates and forecast, 2018 - 2030
  • Fig. 34 Molecular diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 35 Others market estimates and forecast, 2018 - 2030
  • Fig. 36 Red biotechnology market: end use movement analysis
  • Fig. 37 Red biotechnology market: end use outlook and key takeaways
  • Fig. 38 Academic research institutes market estimates and forecasts, 2018 - 2030
  • Fig. 39 CMOs & CROs market estimates and forecasts,2018 - 2030
  • Fig. 40 Pharmaceutical & biotechnology companies market estimates and forecasts,2018- 2030
  • Fig. 41 Others market estimates and forecasts,2018 - 2030
  • Fig. 42 Global red biotechnology market: regional movement analysis
  • Fig. 43 Global red biotechnology market: regional outlook and key takeaways
  • Fig. 44 North America market estimates and forecasts, 2018 - 2030
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 46 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 47 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 48 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 49 UK market estimates and forecasts, 2018 - 2030
  • Fig. 50 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 51 France market estimates and forecasts, 2018 - 2030
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 53 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 54 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 55 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 56 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 57 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 58 China market estimates and forecasts, 2018 - 2030
  • Fig. 59 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 60 India market estimates and forecasts, 2018 - 2030
  • Fig. 61 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 62 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 63 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 64 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 65 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 66 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 67 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 68 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 69 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 70 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 71 Kuwait market estimates and forecasts, 2018 - 2030